Bart Jessen
YOU?
Author Swipe
An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose Open
The first-in-patient (FIP) starting dose for oncology agents should be reasonably safe and provide potential therapeutic benefit to the patient. For late-stage oncology patients, this dose is often based on the ICH S9 guidance, which was d…
Figure S1 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 1 shows the complete, confirmed amino acid sequence of sasanlimab
Figure S9 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 9 shows the SPR analysis of sasanlimab binding to PD-1 from various species
Figure S7 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 7 shows the binding of sasanlimab to PD-1 by ELISA
Figure S10 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 10 shows the selectivity of sasanlimab binding to human and cynomolgus monkey PD-1 using HEK-293T transiently transfected cells and flow cytometry
Data from Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model Open
Immunotherapies targeting the programmed death 1 (PD-1) coinhibitory receptor have shown great promise for a subset of patients with cancer. However, robust and safe combination therapies are still needed to bring the benefit of cancer imm…
View article: Supplemental Table 1 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 1 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S1 shows plasma exposure in humans or rats.
View article: Supplemental Table 1 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 1 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S1 shows plasma exposure in humans or rats.
Figure S8 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 8 shows the solution binding affinity of sasanlimab to human and cynomolgus monkey PD-1 using the KinExA
View article: Supplemental Table 4 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 4 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S4 shows expression change in solute carrier family genes.
Figure S6 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 6 shows the rCGE profile for sasanlimab with two predominant peaks, consistent with L chain and H chain
Figure S2 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 2 shows the confirmation of the primary structure and multi-chain architecture of intact sasanlimab and the identification of the major and minor product isoforms using ESI MS
Figure S2 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 2 shows the confirmation of the primary structure and multi-chain architecture of intact sasanlimab and the identification of the major and minor product isoforms using ESI MS
Data from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Development of antagonistic mAbs that specifically target the immune checkpoint receptor, programmed cell death protein-1 (PD-1), is of great interest for cancer immunotherapy. Here, we report the biophysical characteristics and nonclinica…
Figure S10 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 10 shows the selectivity of sasanlimab binding to human and cynomolgus monkey PD-1 using HEK-293T transiently transfected cells and flow cytometry
Figure S7 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 7 shows the binding of sasanlimab to PD-1 by ELISA
View article: Supplemental Table 3 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 3 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S3 shows A: Most significantly impacted pathways. B: Most significantly impacted upstream regulators.
Figure S15 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 15 shows no body weight changes in response to sasanlimab treatment in mice.
Supplementary Figure Legends from Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model Open
Supplementary Figure Legends
Figure S12 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 12 shows the ELISA assay with the dose-dependent C1q binding to plate-adsorbed sasanlimab and the ADCC assay of sasanlimab performed with activated T cells (target cells) and stimulated PBMCs (effector cells).
View article: Supplemental Table 4 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 4 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S4 shows expression change in solute carrier family genes.
Figure S4 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 4 shows the evaluation of the charge isoform distribution of sasanlimab by imaged capillary isoelectric focusing (iCE).
Figure S12 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 12 shows the ELISA assay with the dose-dependent C1q binding to plate-adsorbed sasanlimab and the ADCC assay of sasanlimab performed with activated T cells (target cells) and stimulated PBMCs (effector cells).
View article: Supplemental Table 2 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 2 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S2 shows IC50 values for CDK4/6 inhibitors in human and rat bone marrow.
Figure S6 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 6 shows the rCGE profile for sasanlimab with two predominant peaks, consistent with L chain and H chain
Figure S4 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 4 shows the evaluation of the charge isoform distribution of sasanlimab by imaged capillary isoelectric focusing (iCE).
View article: Supplemental Figure 1 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Figure 1 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Figure S1 shows duodenum stained with PAS/Alcian blue, and TEM from jejunum.
View article: Supplemental Figure 2 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Figure 2 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Figure S2 shows A) significantly perturbed genes, B) Venn diagram of changed genes, C) hierarchical clustering of changed genes, D) volcano plot of all genes.
Figure S11 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody Open
Supplementary Figure 11 shows sasanlimab binding to human and cynomolgus monkey Fcγ receptor and FcRn